Eupraxia Hits Enrollment Target in Phase 2b EoE Trial
Event summary
- Eupraxia Pharmaceuticals reached its target enrollment of 120 patients in the Phase 2b placebo-controlled portion of the RESOLVE trial for EP-104GI.
- Over 3,000 injections of EP-104GI or vehicle have been administered with no treatment-related Serious Adverse Events (SAEs).
- Interim analysis of the Phase 2b portion is on track for December 2026.
- Statistical reviews confirmed that the sample size does not need adjustment.
The big picture
Eupraxia's successful enrollment in the RESOLVE trial marks a critical step in developing EP-104GI, a potential treatment for Eosinophilic Esophagitis, a disease affecting over 450,000 people in the U.S. The company's Diffusphere™ technology aims to optimize local drug delivery, addressing a significant unmet need in inflammatory gastrointestinal diseases. The positive safety profile observed so far could position EP-104GI as a competitive option in a market with limited therapeutic choices.
What we're watching
- Clinical Efficacy
- How the interim analysis in December 2026 will impact the perceived efficacy of EP-104GI in treating Eosinophilic Esophagitis.
- Regulatory Pathway
- Whether the positive safety data will facilitate a smoother regulatory approval process for EP-104GI.
- Market Adoption
- The pace at which EP-104GI could be adopted by patients and physicians if approved, given its unique local delivery mechanism.
Related topics
